AMARIN CORP PLC\UK (AMRN)
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - General
Amarin Corporation plc
1-25 of 1,527 filings
Recent SEC filings with analysis
- 10-QAmarin reported Q3 2026 total revenue of $39.6 million, down roughly 20% from $49.7 million a year earlier, as VASCEPA product revenue fell to $36.9 million…
- 8-KAmarin reported Q3 2026 net income of $0.2 million, its first profitable quarter in over two years, driven by a 44% reduction in operating expenses following…